American Journal of Ophthalmology
Volume 148, Issue 6 , Pages 925-931.e7 , December 2009

Incorporating Mortality Risk into Estimates of 5-Year Glaucoma Risk

  • Beth Ann Griffin

      Affiliations

    • RAND Corp, Arlington, Virginia
    • Corresponding Author InformationInquiries to Beth Ann Griffin, 1200 South Hayes Street, Arlington, VA 22202
    • ,
  • Marc N. Elliott

      Affiliations

    • RAND Corp, Santa Monica, California
    • ,
  • Anne L. Coleman

      Affiliations

    • Jules Stein Eye Institute, David Geffen School of Medicine, UCLA, Los Angeles, California
    • ,
  • Eric M. Cheng

      Affiliations

    • RAND Corp, Santa Monica, California
    • Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, California

,Accepted 10 July 2009.

References 

  1. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701–713
  2. Robin AL, Frick KD, Katz J, Budenz D, Tielsch JM. The ocular hypertension treatment study: intraocular pressure lowering prevents the development of glaucoma, but does that mean we should treat before the onset of disease?. Arch Ophthalmol. 2004;122:376–378
  3. Jampel HD. We should treat fewer patients with elevated intraocular pressure now that we know the results of the ocular hypertension treatment study. Arch Ophthalmol. 2004;122:378–379
  4. Ocular Hypertension Treatment Study Group and European Glaucoma Prevention Study Group. Validated prediction model for the development of primary open-angle glaucoma in individuals with ocular hypertension. Ophthalmology. 2007;114:10–19
  5. American Academy of Ophthalmology. Preferred Practice Pattern guideline. Primary open-angle glaucoma. September 2005;1–38
  6. Glaucoma 5-year risk estimator based from the Ocular Hypertensive Treatment Study and the European Glaucoma Prevention Study. http://ohts.wustl.edu/risk/calculator.htmlAccessed: October 31, 2008
  7. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245–1251
  8. Min LC, Elliott MN, Wenger NS, Saliba D. Higher vulnerable elders survey scores predict death and functional decline in vulnerable older people. J Am Geriatr Soc. 2006;54:507–511
  9. Saliba D, Elliott M, Rubenstein LZ, et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc. 2001;49:1691–1699
  10. Centers for Disease Control and Prevention. Life Tables. http://www.cdc.gov/nchs/products/life_tables.htmAccessed: May 12, 2009
  11. Medeiros FA, Weinreb RN, Sample PA, et al. Validation of a predictive model to estimate the risk of conversion from ocular hypertension to glaucoma. Arch Ophthalmol. 2005;123:1351–1360
  12. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383
  13. de Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity (a critical review of available methods). J Clin Epidemiol. 2003;56:221–229
  14. Hutchinson TA, Thomas DC, MacGibbon B. Predicting survival in adults with end-stage renal disease: an age equivalence index. Ann Intern Med. 1982;96:417–423
  15. Schneeweiss S, Wang PS, Avorn J, Glynn RJ. Improved comorbidity adjustment for predicting mortality in Medicare populations. Health Serv Res. 2003;38:1103–1120
  16. Gold R, Michael YL, Whitlock EP, et al. Race/ethnicity, socioeconomic status, and lifetime morbidity burden in the women's health initiative: a cross-sectional analysis. J Womens Health (Larchmt). 2006;15:1161–1173
  17. Health Screening Decisions for Older Adults (The American Geriatrics Society). http://www.americangeriatrics.org/products/positionpapers/stopscreening.shtmlAccessed: May 12, 2009
  18. Wilson R, Clarke MG, Ewings P, Graham JD, Macdonagh R. The assessment of patient life-expectancy: how accurate are urologists and oncologists?. BJU International. 2005;95:794–798
  19. Krahn MD, Bremner KE, Asaria J, et al. The ten-year rule revisited: accuracy of clinicians' estimates of life expectancy in patients with localized prostate cancer. Urology. 2002;60:258–263
  20. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol. 2008;53:68–80
  21. Lee DJ, Gomez-Marin O, Lam BL, Zheng DD. Glaucoma and survival: the National Health Interview Survey 1986–1994. Ophthalmology. 2003;110:1476–1483
  22. Grodum K, Heijl A, Bengtsson B. Glaucoma and mortality. Graefes Arch Clin Exp Ophthalmol. 2004;242:397–401
  23. Knudtson MD, Klein BE, Klein R. Age-related eye disease, visual impairment, and survival: the Beaver Dam Eye Study. Arch Ophthalmol. 2006;124:243–249
  24. Borger PH, van Leeuwen R, Hulsman CA, et al. Is there a direct association between age-related eye diseases and mortality? (The Rotterdam Study). Ophthalmology. 2003;110:1292–1296
  25. Harper S, Lynch J, Burris S, Davey Smith G. Trends in the black-white life expectancy gap in the United States, 1983–2003. JAMA. 2007;297:1224–1232
  26. Singh GK, Siahpush M. Widening socioeconomic inequalities in US life expectancy, 1980–2000. Int J Epidemiol. 2006;35:969–979

 Supplemental Material available at AJO.com.

PII: S0002-9394(09)00506-6

doi: 10.1016/j.ajo.2009.07.010

American Journal of Ophthalmology
Volume 148, Issue 6 , Pages 925-931.e7 , December 2009

Article Tools

* Image Usage & Resolution